Evofem Biosciences, Inc.

Good day and thank you for standing by. Welcome to the Evopem Biosciences First Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After this speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. If you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker today, Amy Raskoff. Please go ahead.

Thank you. Good afternoon, everyone. If you haven't done so already, I encourage you to access the press release we issued earlier today and the webcast presentation that accompanies this call, both of which are at evofem.com under the Investors tab. Before we begin, I would like to remind you that remarks on this call will contain forward-looking statements, which are made only as of today, May 6, 2021. For a more detailed description of important risk factors that could cause our actual results to differ materially, please refer to our annual report on Form 10-K and our most recently filed 10-Q. With that, I'll turn the call over to Sondra Pelletier, EvoFem's CEO.

Thank you, Amy, and thank you to everyone for joining us today. The first quarter of 2021, EvoFem delivered strong growth, driven by our Get Sexy DTC campaign, which we launched nationwide on Valentine's Day. Due to the immediate success of this multi-channel marketing campaign and our sales force's persistence during these challenging times to access healthcare providers, we reached new highs across all metrics, including Phexie total brand awareness, total prescriptions, prescriber-based growth, and most importantly, revenue. We expect this campaign will continue to drive consumer awareness and utilization of Phexie for the foreseeable future. In addition to launching a successful DTC campaign, we advanced several important initiatives during the quarter, including our drive to gain a new category for FEXI as a vaginal pH modulator on the FDA's contraceptive categories chart, our collaboration with ENCODA to raise awareness of FEXI in the oncology community, growth to net improvement strategies that are already having a positive impact on our operating results, and discussions with potential partners for commercialization of FEXI in multiple geographies outside of the United States. I'll discuss these initiatives and our expectations for FECSI and our phase three STI prevention clinical trial after our CFO, Jay, files, reviews the financial results, and Russ Behrens, our chief commercial officer, discusses DTC impact.